IFN-γ treatment protocol for MHC-I(lo)/PD-L1(+) pancreatic tumor cells selectively restores their TAP-mediated presentation competence and CD8 T-cell priming potential

BACKGROUND: Many cancer cells express a major histocompatibility complex class I low/ programmed cell death 1 ligand 1 positive (MHC-I(lo)/PD-L1(+)) cell surface profile. For immunotherapy, there is, thus, an urgent need to restore presentation competence of cancer cells with defects in MHC-I proces...

Descripción completa

Detalles Bibliográficos
Autores principales: Stifter, Katja, Krieger, Jana, Ruths, Leonie, Gout, Johann, Mulaw, Medhanie, Lechel, Andre, Kleger, Alexander, Seufferlein, Thomas, Wagner, Martin, Schirmbeck, Reinhold
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Basic Tumor Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7462314/
https://www.ncbi.nlm.nih.gov/pubmed/32868392
http://dx.doi.org/10.1136/jitc-2020-000692

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7462314/
https://www.ncbi.nlm.nih.gov/pubmed/32868392
http://dx.doi.org/10.1136/jitc-2020-000692

Ejemplares similares